Product nameAnti-Myh14 antibody
See all Myh14 primary antibodies
DescriptionRabbit polyclonal to Myh14
Tested applicationsSuitable for: IP, WBmore details
Species reactivityReacts with: Human
Synthetic peptide within Human Myh14 aa 1850-1900. The exact sequence is proprietary.
Database link: Q7Z406
- WB: HEK-293T whole cell lysate. IP: HEK-293T whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab264387 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
|WB||1/2000 - 1/10000. Predicted molecular weight: 228 kDa.|
FunctionCellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
Tissue specificityHigh levels of expression are found in small intestine, colon and skeletal muscle. Expression is low in organs composed mainly of smooth muscle, such as aorta, uterus and urinary bladder. No detectable expression is found in thymus, spleen, placenta and lymphocytes.
Involvement in diseaseDefects in MYH14 are the cause of deafness autosomal dominant type 4A (DFNA4A) [MIM:600652]. A form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.
Defects in MYH14 are the cause of peripheral neuropathy, myopathy, hoarseness, and hearing loss (PNMHH) [MIM:614369]. PNMHH is a complex phenotype of progressive peripheral neuropathy and distal myopathy, with later onset of hoarseness and hearing loss. Affected individuals develop distal muscle weakness at a mean age of 10.6 years, followed by progressive atrophy of these muscles. The lower limbs are more severely affected than the upper limbs, and the muscle weakness first affects anterior leg muscles and later posterior leg muscles.
Sequence similaritiesContains 1 IQ domain.
Contains 1 myosin head-like domain.
DomainThe rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
- Information by UniProt
- 2400004E04Rik antibody
- DFNA4 antibody
- DKFZp667A1311 antibody
All lanes : Anti-Myh14 antibody (ab264387) at 0.1 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 228 kDa
Exposure time: 30 seconds
Lysates prepared using NETN lysis buffer.
Myh14 was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) with ab264387 at 6 µg per reaction. Western blot was performed from the immunoprecipitate using ab264387 at 1 µg/ml.
Lane 1: ab264387 IP in HEK-293T whole cell lysate.
Lane 2: Control IgG IP in HEK-293T whole cell lysate.
Detection: Chemiluminescence with an exposure time of 10 seconds.
Cells prepared using NETN lysis buffer.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264387 has not yet been referenced specifically in any publications.